{"id":31525,"date":"2014-09-19T08:37:33","date_gmt":"2014-09-19T12:37:33","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31525"},"modified":"2014-09-19T08:37:33","modified_gmt":"2014-09-19T12:37:33","slug":"vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525","title":{"rendered":"VIVUS, Inc. (NASDAQ:VVUS) &#8211; Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/19\/2014 (wallstreetpr) \u2013 <a href=\"http:\/\/finance.yahoo.com\/news\/faster-acting-erectile-dysfunction-drug-113715654.html\" target=\"_blank\"><strong>Stendra<\/strong><\/a>, the erectile dysfunction drug developed collaboratively by <strong>VIVUS, Inc. (NASDAQ:VVUS)<\/strong> and <strong>Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL)<\/strong> has been given the nod by the U.S. Food and Drug Administration to be used 15 minutes earlier. It is crucial to point out here that this drug was already approved by the FDA, but only to be used 30 minutes before sexual activity.<\/p>\n<p style=\"text-align: justify;\"><strong>First FDA-Approved ED Drug to be used 15 minutes prior<\/strong><\/p>\n<p style=\"text-align: justify;\">The developers of this drug said yesterday that Stendra is the first erectile dysfunction drug which is approved by FDA to be used just 15 minutes before intercourse.<\/p>\n<p style=\"text-align: justify;\">Meanwhile, the ED drug of <strong>Pfizer Inc. (NYSE:PFE)<\/strong>, Viagra needs to be taken one hour prior. Stendra was given FDA approval in the year 2012 and is accessible to people in various dosages, viz. 200 mg, 100 mg and 50 mg. VIVUS, Inc. (NASDAQ:VVUS) and Auxilium said that Stendra can be consumed by males without\/with food and also with up to three drinks of alcohol.<\/p>\n<p style=\"text-align: justify;\">Among various drugs approved by the USFDA for treating erectile dysfunction, Viagra is among the most commonly used and recognized drug across the world.<\/p>\n<p style=\"text-align: justify;\"><strong>About Stendra<\/strong><\/p>\n<p style=\"text-align: justify;\">Stendra is the drug belonging to the family of phosphodiesterase type 5 inhibitors. This class of drugs caters particularly to the erectile dysfunction patients, whereby, they can enhance blood flow in the direction of penis.<\/p>\n<p style=\"text-align: justify;\"><strong>Rights of Stendra for Vivus and Auxilium<\/strong><\/p>\n<p style=\"text-align: justify;\">While VIVUS, Inc. (NASDAQ:VVUS) holds the commercial rights for this drug for ED across the world (leaving aside a few Asian nations), Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), in the meanwhile; holds exclusive marketing rights for Stendra in Canada and the U.S.<\/p>\n<p style=\"text-align: justify;\"><strong>Sanofi SA (ADR) (NYSE:SNY)<\/strong> is responsible for commercialization of Stendra in Turkey, Middle East and Africa, apart from Commonwealth of Autonomous Countries, which also includes Russia.<\/p>\n<p style=\"text-align: justify;\">In the European Union, Stendra is sold under the commercial name \u201cSpendra.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/19\/2014 (wallstreetpr) \u2013 Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":15971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[9292,7603,7604,2091,993,3599,2745,3275,3600,3598,7233,2090],"stock_ticker":[],"class_list":["post-31525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-auxilium-pharmaceuticals-inc","tag-auxilium-pharmaceuticals-inc-nasdaqauxl","tag-nasdaqauxl","tag-nasdaqvvus","tag-nysepfe","tag-nysesny","tag-pfizer-inc-nysepfe","tag-pfizer-inc","tag-sanofi-sa-adr","tag-sanofi-sa-adr-nysesny","tag-vivus-inc","tag-vivus-inc-nasdaqvvus","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/19\/2014 (wallstreetpr) \u2013 Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-19T12:37:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"324\" \/>\n\t<meta property=\"og:image:height\" content=\"155\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"VIVUS, Inc. (NASDAQ:VVUS) &#8211; Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use\",\"datePublished\":\"2014-09-19T12:37:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg\",\"keywords\":[\"Auxilium Pharmaceuticals Inc.\",\"Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)\",\"NASDAQ:AUXL\",\"NASDAQ:VVUS\",\"NYSE:PFE\",\"NYSE:SNY\",\"Pfizer Inc (NYSE:PFE)\",\"Pfizer Inc.\",\"Sanofi SA (ADR)\",\"Sanofi SA (ADR) (NYSE:SNY)\",\"VIVUS Inc.\",\"Vivus Inc. (NASDAQ:VVUS)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\",\"name\":\"VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg\",\"datePublished\":\"2014-09-19T12:37:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg\",\"width\":324,\"height\":155},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VIVUS, Inc. (NASDAQ:VVUS) &#8211; Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525","og_locale":"en_US","og_type":"article","og_title":"VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use  - Wall Street PR","og_description":"Boston, MA 09\/19\/2014 (wallstreetpr) \u2013 Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-19T12:37:33+00:00","og_image":[{"width":324,"height":155,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"VIVUS, Inc. (NASDAQ:VVUS) &#8211; Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use","datePublished":"2014-09-19T12:37:33+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg","keywords":["Auxilium Pharmaceuticals Inc.","Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)","NASDAQ:AUXL","NASDAQ:VVUS","NYSE:PFE","NYSE:SNY","Pfizer Inc (NYSE:PFE)","Pfizer Inc.","Sanofi SA (ADR)","Sanofi SA (ADR) (NYSE:SNY)","VIVUS Inc.","Vivus Inc. (NASDAQ:VVUS)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525","url":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525","name":"VIVUS, Inc. (NASDAQ:VVUS) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg","datePublished":"2014-09-19T12:37:33+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/vivus.jpg","width":324,"height":155},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-auxilium-pharmaceuticals-inc-nasdaqauxl-stendra-gets-fda-go-ahead-for-15-minutes-prior-use-31525#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"VIVUS, Inc. (NASDAQ:VVUS) &#8211; Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31525"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31525\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/15971"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31525"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}